ESSA Pharma Inc. (EPIX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
SUITE 720 VANCOUVER, BC V5Z 1K5 |
| State of Incorp. | BC |
| Fiscal Year End | September 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2024 MRQ | 12/31/2023 MRQ | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 142,120 | 148,076 | 167,238 | 194,927 | 78,332 | |||
| Cash and cash equivalents | 35,345 | 33,702 | 57,076 | 137,825 | 56,321 | |||
| Short-term investments | 106,775 | 114,374 | 110,161 | 57,102 | 22,011 | |||
| Receivables | 181 | 135 | 6 | 489 | 310 | |||
| Prepaid expense | 1,568 | 585 | 1,816 | 2,182 | 1,600 | |||
| Other undisclosed current assets | 55 | |||||||
| Total current assets: | 143,869 | 148,797 | 169,059 | 197,598 | 80,297 | |||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 363 | 68 | 186 | 308 | ||||
| Deposits noncurrent assets | 257 | 257 | 259 | 259 | 278 | |||
| Total noncurrent assets: | 620 | 325 | 446 | 568 | 278 | |||
| TOTAL ASSETS: | 144,489 | 149,122 | 169,505 | 198,166 | 80,575 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 3,432 | 3,415 | 2,177 | 3,809 | 1,144 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 414 | 321 | 155 | ||
| Accounts payable | 2,600 | 2,028 | 955 | 1,426 | 679 | |||
| Accrued liabilities | 285 | 846 | 807 | 2,062 | 311 | |||
| Other undisclosed accounts payable and accrued liabilities | 547 | 541 | ||||||
| Other undisclosed current liabilities | 99 | 80 | 134 | 121 | 59 | |||
| Total current liabilities: | 3,531 | 3,495 | 2,310 | 3,930 | 1,203 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation: | 76 | 210 | ||||||
| Liabilities, other than long-term debt | 275 | 20 | 127 | |||||
| Operating lease, liability | 275 | 76 | 210 | |||||
| Derivative instruments and hedges, liabilities | 20 | 127 | ||||||
| Other undisclosed noncurrent liabilities | (76) | |||||||
| Total noncurrent liabilities: | 275 | 76 | 231 | 127 | ||||
| Total liabilities: | 3,806 | 3,495 | 2,387 | 4,160 | 1,331 | |||
| Equity | ||||||||
| Equity, attributable to parent | 140,683 | 145,627 | 167,118 | 194,006 | 79,244 | |||
| Common stock | 278,511 | 278,162 | 278,089 | 277,415 | 131,086 | |||
| Additional paid in capital | 49,697 | 49,047 | 44,044 | 36,443 | 31,204 | |||
| Accumulated other comprehensive loss | (2,100) | (2,120) | (2,135) | (2,076) | (2,076) | |||
| Accumulated deficit | (185,426) | (179,461) | (152,879) | (117,776) | (80,970) | |||
| Total equity: | 140,683 | 145,627 | 167,118 | 194,006 | 79,244 | |||
| TOTAL LIABILITIES AND EQUITY: | 144,489 | 149,122 | 169,505 | 198,166 | 80,575 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 TTM | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | ||
|---|---|---|---|---|---|---|---|
| Revenues (Net Investment Income) | 235 | 560 | |||||
| Gross profit: | 235 | 560 | |||||
| Operating expenses | (31,870) | (32,141) | (36,974) | (37,166) | (24,138) | ||
| Operating loss: | (31,870) | (32,141) | (36,974) | (36,931) | (23,578) | ||
| Nonoperating income (expense) | 402 | 7 | 2 | (16) | (45) | ||
| Investment income, nonoperating | 415 | ||||||
| Gain (loss), foreign currency transaction, before tax | (13) | 7 | 2 | (16) | (45) | ||
| Loss from continuing operations before equity method investments, income taxes: | (31,468) | (32,135) | (36,972) | (36,947) | (23,623) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 4,441 | 5,554 | 1,757 | 107 | (111) | ||
| Loss from continuing operations before income taxes: | (27,027) | (26,581) | (35,215) | (36,840) | (23,734) | ||
| Income tax expense (benefit) | (2) | (2) | 112 | 34 | 289 | ||
| Loss from continuing operations: | (27,029) | (26,582) | (35,103) | (36,805) | (23,445) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (35,103) | (36,805) | (23,445) | |
| Other undisclosed net income | 1,224 | ||||||
| Net loss available to common stockholders, diluted: | (25,805) | (26,582) | (35,103) | (36,805) | (23,445) | ||
Comprehensive Income ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 TTM | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (25,805) | (26,582) | (35,103) | (36,805) | (23,445) | ||
| Comprehensive loss: | (25,805) | (26,582) | (35,103) | (36,805) | (23,445) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 5 | 15 | (59) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (25,799) | (26,568) | (35,162) | (36,805) | (23,445) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.